سعر سيجماجريل 75مجم 20 قرص 2022

Sigmagrel 75 mg is an Egyptian clopidogrel 75 mg film-coated tablet product by Sigma, supplied as 20 tablets (2 strips); clopidogrel is a P2Y12 (ADP receptor) antiplatelet agent.

• Acute coronary syndrome: to reduce the rate of myocardial infarction and stroke in non-ST-elevation ACS (unstable angina/NSTEMI), managed medically or with revascularisation, and in STEMI managed medically; given with aspirin.Population: AdultsDailyMed (U.S. National Library of Medicine)
• Recent myocardial infarction, recent stroke or established peripheral arterial disease: to reduce the rate of MI and stroke.Population: AdultsDailyMed (U.S. National Library of Medicine)

• Postmarketing: haemorrhages including fatal cases; agranulocytosis, aplastic anaemia/pancytopenia, TTP, acquired haemophilia A; colitis, pancreatitis, stomatitis, gastric/duodenal ulcer, diarrhoea; acute liver failure, hepatitis; hypersensitivity reactions.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Active pathological bleeding such as peptic ulcer or intracranial haemorrhage.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Hypersensitivity (e.g. anaphylaxis) to clopidogrel or any component.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning: reduced antiplatelet effect in CYP2C19 poor metabolisers (two loss-of-function alleles); tests are available; consider another P2Y12 inhibitor in identified poor metabolisers.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Increases the risk of bleeding; platelet inhibition lasts the lifetime of the platelet (7-10 days).International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Premature discontinuation increases the risk of cardiovascular events; if possible interrupt for 5 days before surgery with major bleeding risk and restart as soon as haemostasis is achieved.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Omeprazole or esomeprazole (CYP2C19 inhibitors)Significantly reduce the antiplatelet activity of clopidogrel; avoid concomitant use.DailyMed (U.S. National Library of Medicine)
• Strong CYP2C19 inducers (e.g. rifampin)Increase active-metabolite levels and platelet inhibition, potentiating bleeding risk; avoid.DailyMed (U.S. National Library of Medicine)
• OpioidsDelay and reduce clopidogrel absorption; consider a parenteral antiplatelet agent in ACS patients needing opioids.DailyMed (U.S. National Library of Medicine)

• Published cases and postmarketing data have not identified drug-associated risks of major birth defects or miscarriage; MI and stroke themselves carry maternal and fetal risks.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• No data on presence in human milk; present in rat milk; no adverse effects seen in a small number of breastfed infants. Weigh benefits against maternal need.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Clopidogrel: Prodrug converted, principally via CYP2C19, to an active metabolite that irreversibly inhibits platelet P2Y12 ADP receptors for the life of the platelet.